Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-26T04:06:02.411Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevention and Management of Late Stage Complications in Parkinson’s Disease

Published online by Cambridge University Press:  18 September 2015

A. Jon Stoessl
A. Jon Stoessl*
Affiliation:
Department of Clinical Neurological Sciences, University of Western Ontario, University Hospital, London
*
Department of Clinical Neurological Sciences, University of Western Ontario, University Hospital, 339 Windermere Road, London, Ontario, Canada N6A 5A5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The major complications of therapy in PD are motor, autonomic and psychiatric. Motor complications may be associated with altered striatal bioavailability of levodopa, and may in part respond to changes in timing of drug administration, redistribution of dietary protein and the use of controlled-release preparations. Since long-term complications seem to be associated with higher cumulative doses of levodopa, the early use of adjunctive agents such as deprenyl and/or dopamine agonists is encouraged. Autonomic effects include impaired bladder and bowel function, impotence and postural hypotension. If conservative measures are ineffective, pharmacotherapy with domperidone, fludrocortisone, indomethacin or adrenergic agents may be required. Depression in PD is associated with decreased levels of noradrenaline and 5-HT and responds to tricyclic antidepressants. Drug-induced psychosis reflects stimulation of mesolimbic-cortical dopamine receptors. Alternatives include reduction of medication, the use of atypical neuroleptics (which may act at novel subtypes of the dopamine receptor) and electroconvulsive therapy.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 19 , Issue S1: 3rd Canadian Conference on Neurodegenerative Diseases , February 1992 , pp. 113 - 116
Copyright
Copyright © Canadian Neurological Sciences Federation 1992

References

1.Marsden, CD, Parkes, JD, Quinn, N.Fluctuations of disability in Parkinson’s disease: clinical aspects. In: Marsden, CD, Fahn, S, eds. Movement Disorders. London: Butterworth, 1982: 96–122.Google Scholar
2.Muenter, MD, Sharpless, NS, Tyce, GM, et al. Patterns of dystonia (‘l-D-l’ and ‘D-I-D’) in response to L-dopa therapy for Parkinson’s disease. Mayo Clin Proc 1977; 52: 163–174.Google Scholar
3.Shoulson, I, Glaubiger, GA, Chase, TN.On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25: 1144–1148.CrossRefGoogle ScholarPubMed
4.Mouradian, MM, Juncos, JL, Fabbrini, G, et al. Motor fluctuations in Parkinson’s disease: pathogenetic and therapeutic strategies. Ann Neurol 1987; 22: 475–479.CrossRefGoogle Scholar
5.Nutt, JG.On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987; 22: 535–540.CrossRefGoogle ScholarPubMed
6.Nutt, JG, Woodward, WR, Hammerstad, JP, et al. The “on-off phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Engl J Med 1984; 310: 483–488.CrossRefGoogle ScholarPubMed
7.Pincus, JH, Barry, K.Protein redistribution diet restores motor function in patients with dopa-resistant “off periods. Neurology 1988; 38: 481–483.CrossRefGoogle ScholarPubMed
8.Fabbrini, G, Juncos, J, Mouradian, MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson’s disease. Ann Neurol 1987; 21: 370–376.CrossRefGoogle ScholarPubMed
9.Mouradian, MM, Heuser, IJE, Baranti, F, et al. Pathogenesis of dyskinesias in Parkinson’s disease. Ann Neurol 1989; 25: 523–526.CrossRefGoogle ScholarPubMed
10.Gancher, ST, Nutt, JG, Woodward, W.Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations. Neurology 1988; 38: 712–716.CrossRefGoogle ScholarPubMed
11.Kempster, PA, Frankel, JP, Bovingdon, M, et al. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989; 52: 718–723.CrossRefGoogle ScholarPubMed
12.Melamed, E, Hefti, F, Wurtman, RJ.Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980; 8: 558–563.CrossRefGoogle ScholarPubMed
13.Cedarbaum, JM, Breck, L, Kutt, H, et al. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson’s disease. Neurology 1987; 37: 1607–1612.CrossRefGoogle ScholarPubMed
14.Martin-Iverson, MT, Stahl, SM, Iversen, SD.Chronic administration of a selective dopamine D-2 agonist: factors determining behavioural tolerance and sensitization. Psychopharmacology 1988; 95: 534–539.CrossRefGoogle ScholarPubMed
15.Juncos, JL, Engber, TM, Raisman, R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989; 25: 473–478.CrossRefGoogle ScholarPubMed
16.Lees, AJ, Shaw, KM, Kohout, LJ, et al. Deprenyl in Parkinson’s disease. Lancet 1977; 2: 791–795.CrossRefGoogle ScholarPubMed
17.Rinne, UK.Combined bromocriptine-levodopa therapy early in Parkinson’s disease. Neurology 1985; 35: 1196–1198.CrossRefGoogle ScholarPubMed
18.Mannisto, PT, Kaakkola, S.Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol Toxicol 1990; 66: 317–323.CrossRefGoogle ScholarPubMed
19.Stibe, CMH, Lees, AJ, Kempster, PA, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 1: 403–406.CrossRefGoogle ScholarPubMed
20.Lees, AJ, Montastruc, JL, Turjanski, N, et al. Sublingual apomorphine and Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989; 52: 1140.CrossRefGoogle ScholarPubMed
21.Lai, S, Laryea, E, Thavundayil, JX, et al. Apomorphine-induced penile tumescence in impotent patients – preliminary results. Prog Neuro-Psychopharm Biol Psychiatry 1987; 11: 235–242.Google Scholar
22.Parkes, JD.Domperidone and Parkinson’s disease. Clin Neuropharmacol 1986; 9: 517–532.CrossRefGoogle ScholarPubMed
23.Mayeux, R, Stern, Y, Cote, L, et al. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology 1984; 34: 642–646.CrossRefGoogle ScholarPubMed
24.Chan-Palay, V, Asan, E.Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson’s disease with and without dementia and depression. J Comp Neurol 1989; 287: 373–392.CrossRefGoogle ScholarPubMed
25.Suchowersky, O, deVries, J.Possible interactions between deprenyl and Prozac. Can J Neurol Sci 1990; 17: 352–353.CrossRefGoogle ScholarPubMed
26.Hand, TH, Hu, X-T, Wang, RY.Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 1987; 415: 257–269.CrossRefGoogle ScholarPubMed
27.Friedman, JH.The management of the levodopa psychoses. Clin Neuropharmacol 1991; 14: 283–295.CrossRefGoogle ScholarPubMed
28.Sawaguchi, T, Goldman-Rakic, PS.D1 dopamine receptors in pre-frontal cortex: involvement in working memory. Science 1991; 251: 947–950.CrossRefGoogle Scholar
29.Sokoloff, P, Giros, B, Martres, M-P, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146–150.CrossRefGoogle ScholarPubMed
30.Van Tol, HHM, Bunzow, JR, Guan, H-C, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610–614.CrossRefGoogle ScholarPubMed
31.Sunahara, RK, Guan, H-C, O’Dowd, BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991; 350: 614–619.CrossRefGoogle ScholarPubMed
32.Anderson, K, Balldin, J, Gottfried, CG.A double-blind evaluation of electroconvulsive therapy in Parkinson’s disease with “on-off phenomena. Acta Neurol Scand 1987; 76: 191–199.CrossRefGoogle Scholar
33.Hurwitz, TA, Calne, DB, Waterman, K.Treatment of dopaminomimetic psychosis in Parkinson’s disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15: 32–34.CrossRefGoogle ScholarPubMed